01—Abstract
Summary
Summary of the 8-K filed August 6, 2025. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported second-quarter 2025 results for the quarter ended June 28, 2025, in a press release furnished as Exhibit 99.1 to this Form 8-K dated August 6, 2025.
Total revenue was $1,032.1 milliona, up 0.6% from $1,026.1 million a year earlier, with organic revenue declining 0.5% after a 1.2% foreign currency benefit. GAAP net income available to common shareholders was $52.3 million, or $1.06 per diluted share, versus $1.74 a year earlier, driven mainly by accelerated amortization of certain CDMO client relationships, restructuring costs, and third-party legal and advisory costs. Non-GAAP diluted EPS rose 11.4% to $3.12 from $2.80, and non-GAAP operating margin improved to 22.1% from 21.3%.
The Discovery and Safety Assessment (DSA) segment, the largest by revenue at $618.0 millionb, saw organic revenue decline 2.4%, while Research Models and Services (RMS) grew organically 2.3% and Manufacturing Solutions grew organically 2.9%. Management said biopharmaceutical demand is stabilizing and that DSA results were better than initially expected. The company also reported that the U.S. Department of Justice had closed the grand jury and parallel civil investigations relating to non-human primate shipments from late 2022 and early 2023.
The company raised its full-year 2025 guidance. Reported revenue growth is now expected to be (2.5)% to (0.5)%, up from (5.5)% to (3.5)%, and organic revenue growth is now (3.0)% to (1.0)%, up from (4.5)% to (2.5)%. GAAP EPS estimate is $4.25 to $4.65c, and non-GAAP EPS estimate is $9.90 to $10.30, up from $9.30 to $9.80.
02—Key points
Key Highlights
- Q2 2025 total revenue of $1,032.1 million, up 0.6% reported and down 0.5% organically; foreign exchange added 1.2%.
- GAAP diluted EPS of $1.06 versus $1.74 a year earlier, reflecting accelerated CDMO client relationship amortization, restructuring costs, and third-party legal and advisory costs.
- Non-GAAP diluted EPS of $3.12, up 11.4% from $2.80; non-GAAP operating margin of 22.1% versus 21.3%.
- DSA segment revenue of $618.0 million, down 2.4% organically, while RMS grew 2.3% and Manufacturing Solutions grew 2.9% organically.
- Full-year 2025 non-GAAP EPS guidance raised to $9.90–$10.30 from $9.30–$9.80; reported revenue growth guidance raised to (2.5)%–(0.5)%.
- U.S. DOJ informed the company that the grand jury and parallel civil investigations into NHP shipments had been closed.
- Share repurchases were significant in the period, with $360.5 million in purchases of treasury stock in the six months ended June 28, 2025.
03—Questions
Frequently Asked Questions
Why did GAAP earnings fall so sharply while non-GAAP earnings rose?
GAAP net income was $52.3 million, or $1.06 per diluted share, compared with $1.74 a year earlier. The filing attributes the decline mainly to higher amortization from accelerated amortization of certain CDMO client relationships, restructuring costs, and third-party legal and advisory costs. Non-GAAP results exclude these items, and non-GAAP diluted EPS rose 11.4% to $3.12, helped by margin gains in all three segments and lower diluted shares from buybacks.
What changed in the 2025 guidance?
The company raised its full-year outlook, citing better-than-expected second-quarter results, particularly in DSA, and a more favorable foreign exchange impact. Non-GAAP EPS is now estimated at $9.90 to $10.30, up from $9.30 to $9.80. Organic revenue growth is now expected at (3.0)% to (1.0)%, versus (4.5)% to (2.5)% previously. GAAP EPS is estimated at $4.25 to $4.65, down from $4.35 to $4.85 in the prior guidance, with restructuring costs now estimated at about $1.40 per share versus about $1.00.
How did the individual business segments perform?
RMS revenue was $213.3 million, up 2.3% organically, with non-GAAP operating margin of 25.3%. DSA revenue was $618.0 million, down 2.4% organically, with non-GAAP operating margin of 27.4%. Manufacturing Solutions revenue was $200.8 million, up 2.9% organically, with non-GAAP operating margin of 32.8%, though its GAAP operating margin fell to 6.0% due to accelerated amortization.
What does the closure of the DOJ investigation mean for the company?
The company stated that in recent weeks the U.S. Department of Justice advised that the grand jury investigation and the parallel civil investigation relating to NHP shipments from late 2022 and early 2023 had been closed. The U.S. Fish and Wildlife Service had also cleared those shipments for legal entry into the United States in July 2025. Third-party legal costs related to these investigations were still included in the company's adjustments for the quarter.
04—Continue